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Deafness is one of the leading causes of disability in 
the world. The prevalence of hearing loss is highest 
in South Asia and sub-Saharan Africa, attributable 
to poor healthcare systems where complications at 
birth as well as infections result in loss of hearing in 
the newborn.[1]
Screening for hearing loss in newborns is standard practice in 
many countries and is the most effective way of detecting hearing 
problems and reducing the negative effects of hearing loss. South 
Africa (SA) does not have a national screening programme. At best, 
only 7.5% of public hospitals provide screening for hearing loss, 
with only 1% providing universal screening.[2] The situation is even 
worse in the rest of sub-Saharan Africa.[3] Clinical presentation of 
hearing loss is extremely heterogeneous, ranging from mild to total 
hearing loss and presenting either as a single symptom or as one of 
many clinical features. The causes of hearing loss can be genetic or 
environmental. A recent review of the aetiology of childhood hearing 
loss showed that 48.3% of cases of hearing loss were of unknown 
cause, 30.4% were genetic and 19.2% were acquired.[4] In developing 
communities, the environment contributes significantly more to 
congenital hearing loss than in the developed world. In Africa, 
bacterial meningitis contributes to cases of hearing loss in infants 
and young children.[3] With improved healthcare there will be a 
reduction in cases of hearing loss caused by disease and an increase 
in the proportion attributable to genetics, the majority of which are 
non-syndromic.[1]
To date, 65 different genes, with many different causative 
mutations, have been identified that contribute to non-syndromic 
deafness.[5] Mutations in gap junction (GJ) genes, specifically GJB2 
(connexin 26), have been shown to be the major contributors to 
deafness globally.[6]
GJ proteins (connexins) regulate 
functions of the cochlea
GJs are intercellular channels that allow ions, second messengers 
and small metabolites to be exchanged by adjacent cells. Connexins 
form intercellular channels by combining in groups of six to form a 
structure called a connexon.[7] Connexons from adjacent cells join 
together to form GJs (Fig. 1, A). The connexin proteins are named 
according to their weight; connexin 26 is a protein with a molecular 
weight of 26 kDa. The two major groups of connexins are the alpha 
and beta connexins, based on sequence similarity of the cytoplasmic 
loop. GJB2 was the second beta connexin gene to be identified. GJB2 
is located on chromosome 13 and codes for the GJ protein connexin 
26. Connexin 26 is involved in the transport of potassium ions and 
other small molecules and is expressed in the cochlea (Fig. 1, B).[8] It 
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is believed that mutations in GJB2 (connexin 
26 gene) affect its ability to transport 
potassium ions and therefore regulate the 
endocochlear potential required for nerve 
impulses involved in hearing, but the mode 
of action is not definitively elucidated.[9]
No mutations in 
connexin genes GJB2, 
GJB6 or GJA1 among 
Cameroonians and 
Xhosa South Africans
With the exception of Ghana,[10] mutations 
in GJB2 (connexin 26) have not been shown 
to be a major contributor to deafness in 
sub-Sahara Africa.[6] Could other potential 
candidate genes, GJB6 (connexin 30) and 
GJA1 (connexin 43), lead to non-syndromic 
deafness in Africans? The GJB6-D13S1830 
deletion is present in up to 9.7% of people 
of European descent,[11] and represents 
the second leading genetic cause of non-
syndromic deafness. When GJA1 mutations 
were detected in African Americans,[12] GJA1 
emerged as a possible candidate for hearing 
loss in indigenous Africans. However, 
failure by investigators to differentiate 
between GJA1 and its pseudogene led to this 
hypothesis being discarded.[13]
We performed a series of molecular 
investigations and reviewed the literature 
with the aim of validating the clinical utility 
of testing for GJB2, GJB6 and GJA1 in the 
African context. As part of this validation, 
we recruited a total of 205 patients affected 
with non-syndromic hearing loss from a 
well-described Cameroonian cohort[3] 
and newly recruited black South Africans 
of Xhosa ancestry, the majority (85%) of 
whom had sensorineural deafness. All 205 
patients were investigated for GJB2 gene, 
as previously reported.[14] A subset of 100 
selected patients, with deafness likely to be 
of genetic cause (mostly familial cases) and 
who did not have any mutation in GJB2 
gene, were investigated for mutations in the 
GJB6 and GJA1 genes.[15]
All the coding regions of GJB2, GJB6 
and GJA1 were amplified and detec-
tion of del(GJB6-D13S1830) was also 
investigated.[14,15] In the GJB2 gene, two 
likely pathogenic mutations were detected 
in two unrelated Cameroonian participants, 
g.3741_3743delTTC (p.F142del) and 
g.3816G>A (p.V167M) in a single individual 
each and in the heterozygous state (Table 1). 
No pathogenic mutation was detected 
among the SA patients.[14] Phylogeny analysis 
of the sequence data from the Cameroonian 
and SA controls, together with that of 
various populations extracted from the 1000 
Genomes Project, shows as expected that 
the SA patients and Cameroonian controls 
grouped with the other African populations. 
There was a low variance when comparing 
sequences in GJB2 in Africans with that 
of other population groups: the principal 
component analysis explains only 40% of 
the variations.[14] Specific sequence variants 
in the GJB2 gene in Africans could therefore 
not explain the low occurrence of mutations 
associated with non-syndromic deafness in 
this population.
In the GJB6 gene, none of the patients 
had the GJB6-D13S1830 deletion. Only one 
variant (rs145762940) was detected, in the 
heterozygous state, in the coding region of 
GJB6, leading to the c.480G>A (p.G160=) 
change.[15] Equally, in the GJA1, five variants 
were detected; one of these occurred in 
the intron, but none were known to be 
pathogenic.[15]
Few mutations in 
GJB2, GJB6 or GJA1 
genes among other 
populations of African 
ancestry
Our report and review of the literature 
confirmed that GJB2 gene is of little 
significance in non-syndromic hearing loss 
in populations of African descent (Table 
1).[10,14,16-20] In addition, by combining data 
from previously unstudied deaf Xhosa patients 
in SA, Cameroonian patients, previous studies 
in Africans and the 1000 Genomes Project, 
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Fig. 1. GJ proteins (connexins) and the inner ear. A: Connexins form intercellular channels by combi­
ning in groups of six to form a structure called a connexon; two connexons from adjacent cells join 
together to form GJs. B: Cross­section through the cochlea. Red cells express connexin 26 (adapted from 
Willems et al.[8]). (GJ = gap junction.)
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the analysis further supported the limited contribution of GJB2 genes 
in non-syndromic hearing loss in Africans. Interestingly, we reported 
two cases of keratitis-ichthyosis-deafness (KID) syndrome in two 
Cameroonian patients,[21] caused by mutations in GJB2. In both cases 
the mutation found (p.Asp50Asn) was the most common in many 
populations globally.[5,22] Adding to the established founder effect of the 
GJB2 mutations reported in European and Asian populations,[5] the data 
indicate that the high frequency of GJB2 mutations in non-syndromic 
hearing loss have evolved in Eurasian populations after their migration 
out of Africa, and spread with population migrations. Finally, at the 
genetic level, the Cameroonian population diversity mimics that of 
various ethnolinguistic groups in African populations;[23] it is anticipated 
that results from a carefully selected sample in this population could 
capture those of many other populations on the African continent.
As in previous studies in Africans,[17] African Americans and 
Caribbean Hispanics with GJB6 mutations,[19] we did not find either 
the GJB6-D13S1830 deletion or coding region changes. Similarly, no 
pathogenic variants were detected in GJA1, suggesting their non-
implication in hearing loss among the Cameroonians and black South 
Africans studied,[15] as has been reported in African Americans.[13]
Clinical implications and research 
perspectives
From our analysis, there is no evidence that mutations in GJB2, 
GJB6 or GJA1 are associated with non-syndromic deafness in sub-
Saharan African patients. We therefore recommend against routine 
use of either gene for clinical testing in patients of African ancestry. 
We suggest that future research should take advantage of the power 
of massively parallel sequencing to screen multiple genes at once. 
This approach has previously been shown to offer the best chance 
of uncovering the genetic causes of deafness in settings with a 
genetically diverse populations.[24]
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